MiNK Therapeutics (INKT) Institutional Ownership $14.20 +1.98 (+16.20%) Closing price 04:00 PM EasternExtended Trading$14.26 +0.06 (+0.39%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for MiNK Therapeutics (NASDAQ:INKT)CurrentInstitutional OwnershipPercentage2.87%Number ofInstitutional Buyers(last 12 months)0Number ofInstitutional Sellers(last 12 months)4TotalInstitutional Outflows(last 12 months)$1.35M Get INKT Insider Trade Alerts Want to know when executives and insiders are buying or selling MiNK Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data INKT Institutional Buying and Selling by Quarter MiNK Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/7/2025 Longbow Finance SA16,667$144K0.0%-90.0%0.420% 2/13/2025Renaissance Technologies LLC101,707$71K0.0%-4.7%2.566% 2/12/2025 Geode Capital Management LLC96,113$67K0.0%-1.9%2.427% 2/7/2025HighTower Advisors LLC50,676$35K0.0%-2.0%1.280% 8/9/2024Renaissance Technologies LLC127,841$121K0.0%+21.5%0.368% 11/14/2023Oracle Investment Management Inc.36,898$41K0.0%-26.9%0.107% 8/14/2023Oracle Investment Management Inc.50,461$106K0.1%N/A0.146% 8/14/2023Deep Track Capital LP324,867$682K0.0%N/A0.941% 8/11/2023Artal Group S.A.228,216$479K0.0%-21.2%0.663% 7/27/2023Virtu Financial LLC14,232$30K0.0%N/A0.041% 2/10/2023StoneX Group Inc.17,821$47K0.0%N/A0.053% 11/4/2022First Republic Investment Management Inc.81,500$172K0.0%N/A0.243% 2/15/2022Sofinnova Investments Inc.345,499$1.54M0.1%N/A1.031% (Data available from 1/1/2016 forward) INKT Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of INKT shares? During the previous two years, the following institutional investors and hedge funds held shares of MiNK Therapeutics shares: Deep Track Capital LP ($682K), Longbow Finance SA ($144K), Renaissance Technologies LLC ($71K), Geode Capital Management LLC ($67K), and Oracle Investment Management Inc. ($41K), HighTower Advisors LLC ($35K).Learn more on MiNK Therapeutics' institutional investors. What percentage of MiNK Therapeutics' stock is owned by institutional investors? 2.87% of MiNK Therapeutics' stock is owned by institutional investors. Learn more on INKT's institutional investor holdings. Which institutional investors have been buying MiNK Therapeutics' stock? The following institutional investors have purchased MiNK Therapeutics' stock in the last 24 months: Deep Track Capital LP ($324.87K), Oracle Investment Management Inc. ($50.46K), and Renaissance Technologies LLC ($22.61K). Which of MiNK Therapeutics' major shareholders have been selling company stock? The following institutional investors have sold MiNK Therapeutics stock in the last 24 months: Longbow Finance SA ($150.00K), Renaissance Technologies LLC ($4.98K), Geode Capital Management LLC ($1.87K), and HighTower Advisors LLC ($1.05K). How much institutional selling is happening at MiNK Therapeutics? Institutional investors have sold a total of 157,899 shares in the last 24 months. This volume of shares sold represents approximately $1.35M in transactions. Related Companies enGene Institutional Ownership GENFIT Institutional Ownership Eupraxia Pharmaceuticals Institutional Ownership C4 Therapeutics Institutional Ownership Innate Pharma Institutional Ownership Puma Biotechnology Institutional Ownership Instil Bio Institutional Ownership Journey Medical Institutional Ownership Cybin Institutional Ownership Aclaris Therapeutics Institutional Ownership This page (NASDAQ:INKT) was last updated on 8/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredElon Musk: “Nothing happens without this…”Lithium has fueled the EV boom, but another resource is even more critical. Without it, over 20 million electr...Behind the Markets | SponsoredTurn your "dead money" into $306+ monthly (starting this month)Turn your "dead money" into $306+ monthly (starting this month) I've been tracking a financial revolution t...Investors Alley | SponsoredMy shocking meeting in Washington, D.C.After a shocking discovery in D.C., Jeff Brown is revealing: President Trump’s “Project MAFA” Get a look...Brownstone Research | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiNK Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MiNK Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access